Must have platelet count ?  x ^/L within  days prior to randomization. Must not have required transfusion of platelets within  week of baseline platelet assessment.
Platelet count >=  X ^/L, within  days prior to administration of study treatment
Platelet count >= , mm^; platelets >= , required for patients who received cycle  of mFOLFOX prior to registration
Platelet count >=  x ^/L measured within  days prior to randomization
Platelet count >=  x ^/L, measured within  days prior to administration of study treatment
Platelet count ? ,/?L, with or without transfusion or cytokine support
Platelet counts >=  x ^/L
Within  (except as noted) days of planned treatment initiation: Platelet count >=   ^/L (>= , per mm^)
Platelet counts >  x ^/L
Platelet count > ,/mm^ ( x ^/L). Must not have required transfusion of platelets within  week of baseline platelet count assessment.
Participants with CR with incomplete count recovery (CRp or CRi) are allowed. Incomplete platelet recovery (CRp) is defined as CR with platelet count <  x /L. Incomplete blood count recovery (CRi) is defined as CR with residual neutropenia <  x /L with or without complete platelet recovery. Red blood cell count (RBC) and platelet transfusion independence is not required.
Platelet counts >=  x ^/L
Platelet count ?   /L (without transfusion or thrombopoietin or thrombopoietin analogues within  weeks of study entry)
Platelet count <  x  (exp)/L
Platelet count ?  x ?/L (?,/cubic millimeters)
Disease-related platelet transfusion within  weeks of registration
Platelet count >= ,/uL without transfusional support in the previous  days
Platelet count < ,/mm^, per PI discretion if thought to be related to underlying myeloma
Within  days of enrollment and with  h of starting lymphodepleting chemotherapy: Platelet count >= ,/mm^.
Platelet count ? ,/mm without transfusion.
Platelet count >=  x ^/L (in absence of blood transfusion).
STRATUM A: Platelet count >= ,/mm^ without support of a platelet transfusion within  days of the test
STRATUM B: Platelet count >= ,/mm^ without support of a platelet transfusion within  days of the test
STRATUM C: Platelet count >= ,/mm^ without support of a platelet transfusion within  days of the test
Platelet count >  k/cumm
Research participant platelet count must be > ,; however, if platelet level is between ,-,, then CAR T-cell infusion may proceed after platelet transfusion is given and the post transfusion platelet count is > ,
Platelet count >= ,/uL (no platelet transfusion within  days prior to obtaining laboratory result)
Platelet count > ,/uL without platelet transfusion within the past  days
Within  days prior to administration of study treatment: Platelet count >=  x ^/L (unless due to bone marrow infiltration by tumor, in which case platelet >=,/ mm^ is allowed).
Within  days (+  day window) of enrollment: Platelet count >=  x ^/L (> , per mm^)
Platelet counts >=,/uL (without transfusion support) results within  days before study drug administration
Platelet count of greater than ,/ul, with no platelet transfusion in prior  weeks
Platelet count < , mm without transfusion support within  days prior to testing
PHASE I: Subjects must have absolute neutrophil count (ANC) > , for  days and platelet transfusion independence as defined as a platelet count > , for  days
PHASE II: Subjects must have ANC > , for  days and platelet transfusion independence as defined as a platelet count > , for  days
Platelet count >=  x ^/L, measured within  days prior to administration of study treatment
FULL STUDY INCLUSION CRITERIA: Platelet count >= ,/mm^, without platelet transfusion within  weeks before the start of study treatment
Performed within  days (+  working days) prior to registration: Platelet count of > ,/mm^ (may be reached by transfusion).
Platelet count of >= ,/mm^ (Note: Transfusion or growth factor may be used for eligibility outside of  days)
Platelet count <   ^/L in the  weeks before screening or platelet transfusion(s) within  weeks before screening
Platelet >  x ^/L without platelet transfusion within  week
Platelet count >= , (platelet [plt]/mm^), with or without transfusion support; NOTE: If the patients bone marrow biopsy shows greater than or equal to % plasma cells, the platelet count should be >  , plt/mm^ (transfusion support or growth factor support is acceptable)
Platelet count of greater than ,/mul, with no platelet transfusion in  weeks prior to registration; this criteria is waived if the thrombocytopenia is due to bone marrow involvement with the disease
Platelet count < ,/microL
Documented platelet refractoriness
Platelet counts > ,/mm^ (without support)
Platelet count >=  x ^/L (measured within  days prior to administration of study treatment)
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Platelet count >= ,/mm^
Platelet count > ,/mm^ (patients who have bone marrow infiltration by MCL are eligible if their platelet level is equal to or > than ,/mm^; these patients should be discussed with either the PI or Co-PI of the study for final approval)
A mean platelet count of < ,/?L, with no individual platelet count > ,/?L; or for those subjects receiving a constant dose of permitted treatments for ITP: a mean platelet count < ,/?L, with no count greater than ,/?L. (Note: The mean platelet count must be determined based on  platelet counts including one obtained within ?  days of first PRTX- dose and the other within ?  days of the first dose of PRTX-.)
Adequate engraftment within  days prior to starting study therapy: ANC ? . x /L without daily use of myeloid growth factor; and platelet ?  x /L without platelet transfusion within  week
Platelet count >= ,/mm^ (no transfusion within  days of enrollment)
Platelet count >=  x ^/mm^ (may be post-transfusion)
Research participant platelet count must be >= ,; however, if platelet level is between ,-,, then T-cell infusion may proceed after platelet transfusion is given and the post transfusion platelet count is >= ,
Relapsed/refractory MCL: Platelet count >= ,/mm^ (transfusion to reach platelet count allowed); (patients who have bone marrow infiltration by MCL are eligible if their platelet level is equal to or > than ,/mm^; these patients should be discussed with either the PI or Co-PI of the study for final approval)
Discontinuation of anti-coagulants and anti-platelet drugs at least  days prior to start of study drug; aspirin  mg is permitted as long as platelet count is >  and there is no evidence of active bleeding or coagulopathy (INR > ., fibrinogen > )
Platelet count >=  x ^/L and able to achieve a platelet count of >=  x ^/L with transfusion support
Platelet ? x ^/L, without transfusion within  days preceding the lab assessment
Platelet count (>=) *^ per liter (L) (prior platelet transfusion is permitted)
Platelet count ? ,/mm (IU: ?   /L) (excluding measurements obtained within  days after a transfusion of platelets).
Platelet count ?, ?L with or without transfusion support
Platelet count >= , performed within  days of enrollment
Platelet count >=  x ^/L within  days prior to administration of study treatment.
Within  days prior to administration of study treatment: Platelet count ?  x ^/L
Platelet count ?  x /L (,/L) without transfusion
Within  days prior to first dose of study drug treatment: Platelet count >=  x /L
Platelet count >= ,/mm^ and no transfusion in prior  weeks, within  days of day .
Within  days of treatment initiation: platelet count >=  x /L
Platelet count >= ,/uL; platelet transfusion is not permitted within  days of screening
Measured within  days prior to administration of study treatment: Platelet count >=  x ^/L
Obtained within  days (or as stipulated) prior to study drug (treatment) administration: platelet count ? ,/ul (without platelet transfusion in the previous  days)
Platelet count >= ,/ul (no platelet transfusion for more than  days)
Patients with a history of platelet alloimmunization
Platelet count >=  x ^/L (no transfusion allowed within  weeks)
Patients on Part C with acute lymphoblastic leukemia: platelet count >= ,/mm^ (may receive platelet transfusions); these patients must not be known to be refractory to red cell or platelet transfusion
Platelet count must be >= ,/mm^ (not achieved by transfusion)
Platelet count >=  x ^/L, measured within  days prior to administration of study treatment
Platelet count must be >= ,/mm^ (not achieved by transfusion) unless due to underlying disease in which case there is no grade restriction
Within  days prior to randomization: Platelet count >= ,/mcL ( x ^/L) without platelet transfusion
Platelets ?  x ^/L; patients with hepatocellular carcinoma may enroll provided they have a platelet count ?  x ^/L.
Platelet count of >  x ? or > % prothrombin activity
Platelet count >=  x ^/L without transfusion, obtained within  days prior to initiation of study treatment
Platelets ?  x ^/L; patients with hepatocellular carcinoma may enroll provided they have a platelet count ?  x ^/L.
B-Platelet count ? xe/L
Platelet count < , cells/mm^ at time of screening evaluation; transfusion may not be used to meet platelet eligibility criteria within  days of obtaining screening evaluation
Platelet count >=  x ^/L without platelet transfusion within  days
A platelet count of at least ,/mm^ on at least  consecutive blood draws at least  week apart with results stable or trending upward is required
Platelet count >=  x ^/mm^ (may be post-transfusion)
At least  weeks ( days) prior to registration: Platelet count >=  x ^/L (no transfusion allowed within  weeks)
Platelet count > ,/uL without platelet transfusion within the past  days
Platelet count ? , ?L with or without transfusion support
Platelet count < , cells/mm^ at time of screening evaluation; transfusion may not be used to meet platelet eligibility criteria within  days of obtaining screening evaluation
Platelet count greater than ,/mm within  weeks prior to initial cryoablation procedure.
Platelet counts ? x ^/L
Platelet count >= ,/m^ (no transfusion within  days of enrollment)
Patients who are platelet refractory prior to initiation of protocol therapy; platelet refractoriness is defined by platelet count <  K when platelet count is obtained  hour post platelet transfusion
Platelet count ?   /L without previous transfusion within  days of first study drug administration
Platelet count >= ,, unless due to underlying lymphoma
Platelet count >= ,/uL (platelet count must be assessed at least  days after a prior transfusion, if any)
Received platelet transfusion within  days prior to Screening evaluations.
The mean of the two platelet counts taken within  month prior to dosing must be =<  x ^/L; platelets counts must reflect pre-transfusion trough results or be obtained no sooner than  week after platelet transfusion to assure stable baseline platelet count; the platelet count obtained should be outside the expected nadir of prior therapies
Platelet count >= ,/mm^ without transfusion support and no abnormal bleeding
Patients >=  days post HCT with platelet count =<  x ^/l sustained for  days or patients are platelet transfusion dependent
Thrombocytopenia with platelet count < xe/L or more than % decrease in platelet count from the highest value achieved after transplant
Platelet count >= ,/mm^ (without platelet transfusion or myeloid growth factor support within two weeks of screening)
Patients must have platelet count >= ,/mm^ within  hours of initiating the induction cycle (for patients with platelets < ,/mm^ at baseline, platelet transfusion support is allowed which is institutional standard of care for AML)
Platelet count must be >= ,/mm^ (not achieved by transfusion)
Platelet count ? , plts/mm (without transfusion); ? , plts/mm for patients with hepatocellular carcinoma only. For hematologic malignancy patients blood counts cited above do not apply
Within  days prior to first study treatment: Platelet count >= ,/^ dL
Platelet count ? ,/mm (without platelet transfusion or growth factor support in the preceding  days);
Platelets ? , cells/?L (with no evidence that this platelet count was induced or supported by a platelet-stimulating agent)
Platelet >=  x ^/L (without transfusion)
Platelet count ?  x ^/L within  days prior to randomization. Must not have required transfusion within  week of baseline platelet assessment.
Platelet count < , mm without transfusion support within  days prior to testing
Adequate neutrophil and platelet counts
Platelet count  x /L without platelet transfusion within one week. Adequate organ function:
Known platelet disorder, such as von Willebrands disease or baseline platelet count of < ,/mm^
Platelet count ? ,/L, with or without transfusion support; platelet count < ,/L but ? ,/L, with or without transfusion support, is permissible if the subject has not had Grade ?  bleeding in the prior  months (where grading of the bleeding is determined per the National Cancer Institute's Common Terminology Criteria for Adverse Events [CTCAE], version .)
Platelet count >=  x ^/L (without transfusion support within  weeks of registration)
Platelet count >= ,/mm^ (may receive platelet transfusions); these patients must not be known to be refractory to red cell or platelet transfusion
Patient requiring platelet transfusion threshold of >  x ^/L
Failure to achieve platelet engraftment (defined as platelet count >=  x ^/L on  consecutive measurements without transfusion for  days) by day + post UCBT
Patients requiring more than one platelet transfusion per day
Anticipated platelet count =<  x ^/L for >=  days within  hours of enrollment
Platelet count >= ,/uL (>  hours since prior platelet transfusion)
Patients must either have grade  thrombocytopenia (platelet counts <  x ^/L) due to chemotherapy unless transfusion within - hours
Subjects must have a platelet count of >= , to receive immunizations; patients requiring platelet transfusions are eligible to enroll and must have a platelet count >= , within  hours prior to their immunization, or platelet count >= , without transfusion documented within  days for subjects <  months post-transplant and within  days for subjects - months post-transplant
FOR THE  SUBJECTS ENROLLED IN YEAR : Subjects must have a platelet count of >= , to receive the immunizations; patients requiring platelet transfusions are eligible to enroll and must have a platelet count >= , within  hours prior to their immunization, or platelet count >= , without transfusion documented within  days for subjects <  months post-transplant and within  days for subjects - months post-transplant
Subjects must have a platelet count of >= , to receive the immunizations; patients requiring platelet transfusions are eligible to enroll and must have a platelet count >= , within  hours prior to their immunization; for subjects <  months post-transplant, if a platelet count of >= , is documented without transfusion support within  days of the immunization, then an additional platelet count does not need to be repeated prior to immunization; for subjects - months post-transplant, if a platelet count of >= , is documented without transfusion support within  days of the immunization, then an additional platelet count does not need to be repeated prior to immunization
Measured within  days prior to administration of study treatment: Platelet count >=  x ^/L
Platelet count of < , that cannot be corrected with transfusion
Platelet count >= ,/mm^ without transfusion support >  days prior to registration
Platelet count >= ,/mm^ (without transfusion within  weeks prior to cycle , day )
Platelet counts ?,/mm (?/L)